EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Methylglyoxal in Cardiometabolic Disorders: Routes Leading to Pathology Counterbalanced by Treatment Strategies

Izabela Berdowska iD, Małgorzata Matusiewicz iD, Izabela Fecka iD

Molecules · 2023

DOI: 10.3390/molecules28237742 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2023. Verfasst von Izabela Berdowska und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Wroclaw Medical University, 50-368 Wroclaw, Poland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Hyperglycemia, Cardiovascular Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 296 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methylglyoxal (MGO) is the major compound belonging to reactive carbonyl species (RCS) responsible for the generation of advanced glycation end products (AGEs). Its upregulation, followed by deleterious effects at the cellular and systemic levels, is associated with metabolic disturbances (hyperglycemia/hyperinsulinemia/insulin resistance/hyperlipidemia/inflammatory processes/carbonyl stress/oxidative stress/hypoxia). Therefore, it is implicated in a variety of disorders, including metabolic syndrome, diabetes mellitus, and cardiovascular diseases. In this review, an interplay between pathways leading to MGO generation and scavenging is addressed in regard to this system’s impairment in pathology. The issues associated with mechanistic MGO involvement in pathological processes, as well as the discussion on its possible causative role in cardiometabolic diseases, are enclosed. Finally, the main strategies aimed at MGO and its AGEs downregulation with respect to cardiometabolic disorders treatment are addressed. Potential glycation inhibitors and MGO scavengers are discussed, as well as the mechanisms of their action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes MellitusHyperglycemiaCardiovascular DiseasesHumansPyruvaldehydeGlycation End Products, AdvancedMagnesium Oxide

Stichwörter der Autor:innen

MG-H1advanced glycation end productscardiovascular diseasediabetes mellitusglyoxalaseinsulin resistancemetabolic syndromemetforminmethylglyoxalmethylglyoxal scavengers

Substanzen

PyruvaldehydeGlycation End Products, AdvancedMagnesium Oxide

Autor:innen und Institutionen

  • Department of Medical Biochemistry, Wroclaw Medical University, 50-368 Wroclaw, Poland.
  • Department of Pharmacognosy and Herbal Medicines, Wroclaw Medical University, 50-556 Wroclaw, Poland.

ORCID-Profile: Izabela Berdowska, Małgorzata Matusiewicz, Izabela Fecka

Zitieren

APA

Berdowska, I., Matusiewicz, M., & Fecka, I. (2023). Methylglyoxal in Cardiometabolic Disorders: Routes Leading to Pathology Counterbalanced by Treatment Strategies. Molecules. https://doi.org/10.3390/molecules28237742

Vancouver

Berdowska I, Matusiewicz M, Fecka I. Methylglyoxal in Cardiometabolic Disorders: Routes Leading to Pathology Counterbalanced by Treatment Strategies. Molecules. 2023. doi:10.3390/molecules28237742

BibTeX
@article{Berdowska2023,
  author = {Berdowska, Izabela and Matusiewicz, Małgorzata and Fecka, Izabela},
  title = {Methylglyoxal in Cardiometabolic Disorders: Routes Leading to Pathology Counterbalanced by Treatment Strategies},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28237742}
}
Kostenlos starten →